MGC Pharmaceuticals (ASX:MXCDA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MXCDA Stock Overview

A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.

About the company

MXCDA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 17.9% per year over past 5 years

Negative shareholders equity

Does not have a meaningful market cap (A$2M)

Shareholders have been substantially diluted in the past year

+ 2 more risks

Argent BioPharma Limited Competitors

Wellfully

ASX:WFL

AU$1.5m

Althea Group Holdings

ASX:AGH

AU$18.8m

Cann Global

ASX:CGB

AU$5.4m

Rhinomed

ASX:RNO

AU$11.5m

Price History & Performance

Summary of all time highs, changes and price drops for MGC Pharmaceuticals
Historical stock prices
Current Share Price	AU$0.47
52 Week High	AU$1.00
52 Week Low	AU$0.41
Beta	1.34
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-55.81%

Recent updates

Shareholder Returns

	MXCDA	AU Pharmaceuticals	AU Market
7D	-32.6%	2.7%	0.3%
1Y	n/a	100.4%	16.1%

Return vs Industry: Insufficient data to determine how MXCDA performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MXCDA performed against the Australian Market.

Price Volatility

Is MXCDA's price volatile compared to industry and market?
MXCDA volatility
MXCDA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.6%

Stable Share Price: MXCDA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine MXCDA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Roby Zomer	argentbiopharma.com

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.

Argent BioPharma Limited Fundamentals Summary

How do MGC Pharmaceuticals's earnings and revenue compare to its market cap?
MXCDA fundamental statistics
Market cap	AU$2.46m
Earnings (TTM)	-AU$20.82m
Revenue (TTM)	AU$3.39m

0.7x

P/S Ratio

-0.1x

P/E Ratio

Is MXCDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MXCDA income statement (TTM)
Revenue	AU$3.39m
Cost of Revenue	AU$2.10m
Gross Profit	AU$1.29m
Other Expenses	AU$22.11m
Earnings	-AU$20.82m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.70
Gross Margin	37.98%
Net Profit Margin	-614.71%
Debt/Equity Ratio	-114.3%

How did MXCDA perform over the long term?

See historical performance and comparison

MGC Pharmaceuticals ASX:MXCDA Stock Report